Header Logo

Connection

Mary Rusckowski to Morpholinos

This is a "connection" page, showing publications Mary Rusckowski has written about Morpholinos.
Connection Strength

1.780
  1. Chen L, Wang Y, Cheng D, Liu X, Dou S, Liu G, Hnatowich DJ, Rusckowski M. (99m)Tc-MORF oligomers specific for bacterial ribosomal RNA as potential specific infection imaging agents. Bioorg Med Chem. 2013 Nov 01; 21(21):6523-30.
    View in: PubMed
    Score: 0.433
  2. Wang Y, Chen L, Liu X, Cheng D, Liu G, Liu Y, Dou S, Hnatowich DJ, Rusckowski M. Detection of Aspergillus fumigatus pulmonary fungal infections in mice with (99m)Tc-labeled MORF oligomers targeting ribosomal RNA. Nucl Med Biol. 2013 Jan; 40(1):89-96.
    View in: PubMed
    Score: 0.410
  3. Chen L, Cheng D, Liu G, Dou S, Wang Y, Liu X, Liu Y, Rusckowski M. Detection of Klebsiella. Pneumoniae Infection with an Antisense Oligomer Against its Ribosomal RNA. Mol Imaging Biol. 2016 08; 18(4):527-34.
    View in: PubMed
    Score: 0.133
  4. Dou S, Wang Y, Barton B, Chen L, Rusckowski M, Shultz LD, Greiner DL, Liu G. Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach. Nucl Med Biol. 2014 Jan; 41(1):127-31.
    View in: PubMed
    Score: 0.109
  5. Dou S, Smith M, Wang Y, Rusckowski M, Liu G. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy. Cancer Biother Radiopharm. 2013 May; 28(4):335-42.
    View in: PubMed
    Score: 0.105
  6. Liu G, Dou S, Akalin A, Rusckowski M, Streeter PR, Shultz LD, Greiner DL. Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody. Nucl Med Biol. 2012 Jul; 39(5):645-51.
    View in: PubMed
    Score: 0.097
  7. Liu G, Dou S, Liu Y, Wang Y, Rusckowski M, Hnatowich DJ. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy. Bioconjug Chem. 2011 Dec 21; 22(12):2539-45.
    View in: PubMed
    Score: 0.095
  8. Liu G, Dou S, Cheng D, Leif J, Rusckowski M, Streeter PR, Shultz LD, Hnatowich DJ, Greiner DL. Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model. Mol Pharm. 2011 Jun 06; 8(3):767-73.
    View in: PubMed
    Score: 0.023
  9. Liu G, Dou S, Chen X, Chen L, Liu X, Rusckowski M, Hnatowich DJ. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted. Cancer Biother Radiopharm. 2010 Dec; 25(6):757-62.
    View in: PubMed
    Score: 0.022
  10. Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther. 2010 Oct 15; 10(8):767-74.
    View in: PubMed
    Score: 0.022
  11. Cheng D, Wang Y, Liu X, Pretorius PH, Liang M, Rusckowski M, Hnatowich DJ. Comparison of 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice. Bioconjug Chem. 2010 Aug 18; 21(8):1565-70.
    View in: PubMed
    Score: 0.022
  12. Liu X, Nakamura K, Wang Y, Cheng D, Liang M, Xiao N, Chen L, Rusckowski M, Hnatowich DJ. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle. J Biomed Nanotechnol. 2010 Apr; 6(2):153-7.
    View in: PubMed
    Score: 0.021
  13. Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging. 2010 Jun; 54(3):333-40.
    View in: PubMed
    Score: 0.021
  14. Wang Y, Liu X, Chen L, Cheng D, Rusckowski M, Hnatowich DJ. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Eur J Nucl Med Mol Imaging. 2009 Dec; 36(12):1977-86.
    View in: PubMed
    Score: 0.021
  15. Liu G, Dou S, Liang M, Chen X, Rusckowski M, Hnatowich DJ. The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size. Eur J Cancer. 2009 Nov; 45(17):3098-103.
    View in: PubMed
    Score: 0.021
  16. Wang Y, Liu X, Nakamura K, Chen L, Rusckowski M, Hnatowich DJ. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles. Cancer Biother Radiopharm. 2009 Oct; 24(5):573-8.
    View in: PubMed
    Score: 0.021
  17. Liu G, Cheng D, Dou S, Chen X, Liang M, Pretorius PH, Rusckowski M, Hnatowich DJ. Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation. Mol Imaging Biol. 2009 Sep-Oct; 11(5):303-7.
    View in: PubMed
    Score: 0.020
  18. Chen X, Dou S, Liu G, Liu X, Wang Y, Chen L, Rusckowski M, Hnatowich DJ. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjug Chem. 2008 Aug; 19(8):1518-25.
    View in: PubMed
    Score: 0.019
  19. Liu G, Dou S, Rusckowski M, Hnatowich DJ. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther. 2008 May; 7(5):1025-32.
    View in: PubMed
    Score: 0.019
  20. Liu G, Dou S, Pretorius PH, Liu X, Rusckowski M, Hnatowich DJ. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur J Nucl Med Mol Imaging. 2008 Feb; 35(2):272-80.
    View in: PubMed
    Score: 0.018
  21. Zhang S, Liu G, Liu X, Yin D, Dou S, He J, Rusckowski M, Hnatowich DJ. Comparison of several linear fluorophore- and quencher-conjugated oligomer duplexes for stability, fluorescence quenching, and kinetics in vitro and in vivo in mice. Bioconjug Chem. 2007 Jul-Aug; 18(4):1170-5.
    View in: PubMed
    Score: 0.018
  22. He J, Liu G, Dou S, Gupta S, Rusckowski M, Hnatowich D. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug Chem. 2007 May-Jun; 18(3):983-8.
    View in: PubMed
    Score: 0.017
  23. Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging. 2007 Feb; 34(2):237-46.
    View in: PubMed
    Score: 0.017
  24. He J, Rusckowski M, Wang Y, Dou S, Liu X, Zhang S, Liu G, Hnatowich DJ. Optical pretargeting of tumor with fluorescent MORF oligomers. Mol Imaging Biol. 2007 Jan-Feb; 9(1):17-23.
    View in: PubMed
    Score: 0.017
  25. Liu G, Dou S, Mardirossian G, He J, Zhang S, Liu X, Rusckowski M, Hnatowich DJ. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Clin Cancer Res. 2006 Aug 15; 12(16):4958-64.
    View in: PubMed
    Score: 0.017
  26. Liu G, Dou S, He J, Yin D, Gupta S, Zhang S, Wang Y, Rusckowski M, Hnatowich DJ. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot. 2006 Sep; 64(9):971-8.
    View in: PubMed
    Score: 0.016
  27. He J, Liu G, Zhang S, Rusckowski M, Hnatowich DJ. Pharmacokinetics in mice of four oligomer-conjugated polymers for amplification targeting. Cancer Biother Radiopharm. 2003 Dec; 18(6):941-7.
    View in: PubMed
    Score: 0.014
  28. He J, Liu G, Zhang S, Vanderheyden JL, Liu N, Liu C, Zhang Y, Gupta S, Rusckowski M, Hnatowich DJ. A comparison of in vitro and in vivo stability in mice of two morpholino duplexes differing in chain length. Bioconjug Chem. 2003 Sep-Oct; 14(5):1018-23.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.